MorphoSys's Licensee Janssen has Reported That New TremfyaR Guselkumab 3Year Data Shows Stably Maintained Rates of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis news with additional features

DGAPNews MorphoSys AG Key words Study19.10.2018 1528 The issuer is solely responsible for the content of this announcement.PlaneggMunich Germany October 19 2018MorphoSys's Licensee Janssen has Reported That New TremfyaR Guselkumab 3Year Data Shows Stably...